Day One Biopharmaceuticals, Inc. – NASDAQ:DAWN

Add to watchlist

$6.81

-6.06

-47.09%

Market closed

Open in about 12 hours

-15.38%

month

-15.38%

quarter

-14.88%

year

Market Cap	1.27B
Enterprise value	750.25M

P/E	-5.99
EV/Sales	N/A
EV/EBITDA	-5.48
Price/Sales	N/A
Price/Book	2.51
PEG ratio	-0.11
EPS	-2.48

Revenue	N/A
EBITDA	-235.09M
Income	-208.93M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN): Profit margin
Jun 2023	0	-45.86M
Sep 2023	0	-46.15M
Dec 2023	560K	-54.51M	-9734.11%
Mar 2024	0	-62.41M

Day One Biopharmaceuticals Financials Estimate

Q Y

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN): Analyst Estimates
Mar 2024	0	-62.41M
Sep 2025	32.85M	-33.38M	-101.6%
Oct 2025	32.85M	-42.40M	-129.06%
Dec 2025	40.06M	-39.22M	-97.91%

Analysts Price target
Financials & Ratios estimates

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN): Earnings per share (EPS)
2023-11-06	-0.6	-0.54
2024-02-26	-0.57	-0.64
2024-05-06	-0.67	-0.72

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN): Debt to assets
Jun 2023	450756000	24.70M	5.48%
Sep 2023	414179000	818.25M	197.56%
Dec 2023	376048000	29.50M	7.85%
Mar 2024	326645000	29.83M	9.13%

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN): Cash Flow
Jun 2023	-42.43M	20.27M	162.10M
Sep 2023	-37.06M	88.91M	115K
Dec 2023	-41.37M	30.38M	597K
Mar 2024	-49.72M	89.28M	48K

Day One Biopharmaceuticals alternative data

Day One Biopharmaceuticals
Employees

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN): Employee count
Sep 2023	124
Oct 2023	124
Nov 2023	124
Dec 2023	133
Jan 2024	133
Feb 2024	133
Mar 2024	155
Apr 2024	155
May 2024	155
Jun 2024	174
Jul 2024	174

Day One Biopharmaceuticals
Hedge Funds Holdings Q1 2023

37.43% -47.39%

of DAWN is owned by hedge funds

63 -43

hedge funds hold DAWN stock

24.50M -35.72M

shares is hold by hedge funds

DAWN hedge funds holdings changes

Day One Biopharmaceuticals
Insider Trading

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN): Insider trades (number of shares)
Period	Buy	Sel
Feb 2024	0	35781
Mar 2024	0	40000
Apr 2024	0	10000
May 2024	0	113357
Jun 2024	0	40000
Jul 2024	0	20000
Aug 2024	827586	18748
Sep 2024	0	30000
Oct 2024	0	500
Nov 2024	0	58027
Dec 2024	0	30000

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	10 Dec 2024	BLACKMAN SAMUEL C. officer: HEAD OF ..	Common Stock	30,000	$13.31	$399,330
Sale	18 Nov 2024	BENDER JEREMY director, officer: CHIEF EXECUTIVE OFFICER director, officer: CHIEF EXECUT..	Common Stock	10,554	$13.21	$139,418
Sale	18 Nov 2024	BLACKMAN SAMUEL C. officer: HEAD OF ..	Common Stock	2,206	$13.21	$29,141
Sale	18 Nov 2024	DUBOW ADAM officer: GENERAL COUNSEL officer: GENERAL COUNSEL	Common Stock	3,165	$13.21	$41,810
Sale	18 Nov 2024	YORK CHARLES N II officer: COO, CFO AND SECRETARY officer: COO, CFO AND SECRETARY	Common Stock	2,602	$13.21	$34,372
Option	15 Nov 2024	BENDER JEREMY director, officer: CHIEF EXECUTIVE OFFICER director, officer: CHIEF EXECUT..	Restricted Stock Unit (RSU)	11,687	N/A	N/A
Option	15 Nov 2024	BENDER JEREMY director, officer: CHIEF EXECUTIVE OFFICER director, officer: CHIEF EXECUT..	Common Stock	11,687	N/A	N/A
Option	15 Nov 2024	BENDER JEREMY director, officer: CHIEF EXECUTIVE OFFICER director, officer: CHIEF EXECUT..	Common Stock	4,750	N/A	N/A
Option	15 Nov 2024	BENDER JEREMY director, officer: CHIEF EXECUTIVE OFFICER director, officer: CHIEF EXECUT..	Common Stock	3,562	N/A	N/A
Option	15 Nov 2024	BENDER JEREMY director, officer: CHIEF EXECUTIVE OFFICER director, officer: CHIEF EXECUT..	Restricted Stock Unit (RSU)	4,750	N/A	N/A

DAWN insider trading transactions

Day One Biopharmaceuticals
Executives

Insider	Age	Compensation
Dr. Jeremy Bender M.B.A., Ph.D. (1972) Chief Executive Officer, Pres & Director	53	$481,360
Dr. Samuel C. Blackman M.D., Ph.D. (1969) Co-Founder & Chief Medical Officer	56	$477,100
Ms. Julie Papanek Grant M.B.A. (1982) Co-Founder & Chair of the Board	43	$62,910

Day One Biopharmaceuticals
Latest News

Thursday, 26 December 2024
14:10	3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2025	zacks.com
Wednesday, 25 December 2024
07:31	Day One Biopharmaceuticals: Sales Figures In The Crosshairs	seekingalpha.com
Tuesday, 17 December 2024
08:30	Day One to Present at the 43rd Annual J.P. Morgan Healthcare Conference	globenewswire.com
Wednesday, 20 November 2024
16:30	Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development	globenewswire.com
Monday, 18 November 2024
08:30	Day One to Participate in the Piper Sandler 36th Annual Healthcare Conference	globenewswire.com
Wednesday, 6 November 2024
10:55	Wall Street Analysts See a 136.83% Upside in Day One Biopharmaceuticals (DAWN): Can the Stock Really Move This High?	zacks.com
Wednesday, 30 October 2024
22:57	Day One Biopharmaceuticals, Inc. (DAWN) Q3 2024 Earnings Call Transcript	seekingalpha.com
18:20	Day One Biopharmaceuticals, Inc. (DAWN) Surpasses Q3 Earnings and Revenue Estimates	zacks.com
16:01	Day One Reports Third Quarter 2024 Financial Results and Corporate Progress	globenewswire.com
10:05	SUNDECK 3200 HERALDS IN A NEW DAWN FOR HURRICANE BOATS	prnewswire.com
Monday, 21 October 2024
10:55	Wall Street Analysts Think Day One Biopharmaceuticals (DAWN) Could Surge 140.71%: Read This Before Placing a Bet	zacks.com
Wednesday, 16 October 2024
08:30	Day One to Report Third Quarter 2024 Financial Results Wednesday, October 30, 2024	globenewswire.com
Wednesday, 14 August 2024
11:46	Bank of America Says Buy These 3 Stocks for a Double-Digit Rally	investorplace.com
Tuesday, 30 July 2024
09:40	Day One Biopharmaceuticals, Inc. (DAWN) Reports Q2 Loss, Tops Revenue Estimates	zacks.com
07:30	Day One Reports Second Quarter 2024 Financial Results and Corporate Progress	globenewswire.com
07:00	Day One Announces Oversubscribed $175.0 Million Private Placement	globenewswire.com
Thursday, 25 July 2024
00:58	Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor	globenewswire.com
Wednesday, 19 June 2024
11:30	Day One (DAWN) In-Licenses MabCare Cancer Candidate, Stock Up	zacks.com
Tuesday, 18 June 2024
08:30	Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers	globenewswire.com
Thursday, 30 May 2024
08:30	Day One Announces Sale of Priority Review Voucher for $108 Million	globenewswire.com
Monday, 6 May 2024
16:30	Day One Reports First Quarter 2024 Financial Results and Corporate Progress	globenewswire.com
Tuesday, 23 April 2024
15:56	Day One's OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor	globenewswire.com
Monday, 26 February 2024
16:30	Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress	globenewswire.com
Thursday, 1 February 2024
10:07	Navigating Day One Biopharmaceuticals' Financial Health And Clinical Prospects	seekingalpha.com
Tuesday, 19 December 2023
08:00	Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference	GlobeNewsWire
Sunday, 23 July 2023
04:43	Diving Into Day One Biopharmaceuticals	Seeking Alpha
Monday, 5 June 2023
12:30	Why Shares of Day One Pharmaceuticals Are Up Monday	The Motley Fool
08:09	Day One Biopharmaceuticals shares jump 23% on positive results for glioma treatment	Market Watch
Monday, 1 May 2023
14:39	Day One Biopharmaceuticals stock rallies as 1Q results show the brain tumor treatment candidate producer is funded into 2025	Proactive Investors
Friday, 7 April 2023
07:37	Day One Biopharmaceuticals: Strong Potential, Price Drop Opportunity, Some Concerns	Seeking Alpha

Frequently Asked Questions (FAQ)

What's the price of Day One Biopharmaceuticals stock today?

One share of Day One Biopharmaceuticals stock can currently be purchased for approximately $6.81.
When is Day One Biopharmaceuticals's next earnings date?

Unfortunately, Day One Biopharmaceuticals's (DAWN) next earnings date is currently unknown.
Does Day One Biopharmaceuticals pay dividends?

No, Day One Biopharmaceuticals does not pay dividends.
How much money does Day One Biopharmaceuticals make?

Day One Biopharmaceuticals has a market capitalization of 1.27B. Day One Biopharmaceuticals made a loss 188.92M US dollars in net income (profit) last year or -$0.72 on an earnings per share basis.
What is Day One Biopharmaceuticals's stock symbol?

Day One Biopharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "DAWN".
What is Day One Biopharmaceuticals's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Day One Biopharmaceuticals?

Shares of Day One Biopharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Day One Biopharmaceuticals's key executives?
Day One Biopharmaceuticals's management team includes the following people:
- Dr. Jeremy Bender M.B.A., Ph.D. Chief Executive Officer, Pres & Director(age: 53, pay: $481,360)
- Dr. Samuel C. Blackman M.D., Ph.D. Co-Founder & Chief Medical Officer(age: 56, pay: $477,100)
- Ms. Julie Papanek Grant M.B.A. Co-Founder & Chair of the Board(age: 43, pay: $62,910)
Is Day One Biopharmaceuticals founder-led company?

Yes, Day One Biopharmaceuticals is a company led by its founders Dr. Samuel C. Blackman M.D., Ph.D. and Ms. Julie Papanek Grant M.B.A..
How many employees does Day One Biopharmaceuticals have?

As Jul 2024, Day One Biopharmaceuticals employs 174 workers, which is 12% more then previous quarter.
When Day One Biopharmaceuticals went public?

Day One Biopharmaceuticals, Inc. is publicly traded company for more then 4 years since IPO on 27 May 2021.
What is Day One Biopharmaceuticals's official website?

The official website for Day One Biopharmaceuticals is dayonebio.com.
Where are Day One Biopharmaceuticals's headquarters?

Day One Biopharmaceuticals is headquartered at 395 Oyster Point Boulevard, South San Francisco, CA.
How can i contact Day One Biopharmaceuticals?

Day One Biopharmaceuticals's mailing address is 395 Oyster Point Boulevard, South San Francisco, CA and company can be reached via phone at +65 04840899.

Day One Biopharmaceuticals, Inc.

dayonebio.com

Exchange:

NASDAQ

Full time employees:

174

Industry:

Biotechnology

Sector:

Healthcare

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

+65 04840899

395 Oyster Point Boulevard
South San Francisco, CA 94080

CIK: 0001845337
ISIN: US23954D1090
CUSIP: 23954D109